Clinical characteristics of hypersensitivity pneumonitis: non-fibrotic and fibrotic subtypes

被引:2
|
作者
Chen, Xueying [1 ]
Yang, Xiaoyan [2 ]
Ren, Yanhong [1 ]
Xie, Bingbing [1 ]
Xie, Sheng [3 ]
Zhao, Ling [4 ]
Wang, Shiyao [1 ]
Geng, Jing [1 ]
Jiang, Dingyuan [1 ]
Luo, Sa [1 ]
He, Jiarui [1 ]
Shu, Shi [1 ]
Hu, Yinan [1 ]
Zhu, Lili [1 ]
Li, Zhen [1 ]
Zhang, Xinran [5 ]
Liu, Min [3 ]
Dai, Huaping [1 ,6 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll, Ctr Resp Med, China Japan Friendship Hosp,Natl Ctr Resp Med,Natl, Beijing 100029, Peoples R China
[2] Capital Med Univ, China Japan Friendship Hosp, Ctr Resp Med, Dept Pulm & Crit Care Med, Beijing 100029, Peoples R China
[3] China Japan Friendship Hosp, Dept Radiol, Beijing 100029, Peoples R China
[4] China Japan Friendship Hosp, Dept Pathol, Beijing 100029, Peoples R China
[5] China Japan Friendship Hosp, Inst Clin Med Sci, Ctr Resp Med, Beijing 100029, Peoples R China
[6] China Japan Friendship Hosp, Dept Pulm & Crit Care Med, Beijing 100029, Peoples R China
关键词
Interstitial lung disease; Hypersensitivity pneumonitis; Clinical characteristics; Fibrosis; Prognosis; LUNG; SURVIVAL; ANTIGEN; DISEASE; COHORT;
D O I
10.1097/CM9.0000000000002613
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The presence of fibrosis is a criterion for subtype classification in the newly updated hypersensitivity pneumonitis (HP) guidelines. The present study aimed to summarize differences in clinical characteristics and prognosis of non-fibrotic hypersensitivity pneumonitis (NFHP) and fibrotic hypersensitivity pneumonitis (FHP) and explore factors associated with the presence of fibrosis.Methods: In this prospective cohort study, patients diagnosed with HP through a multidisciplinary discussion were enrolled. Collected data included demographic and clinical characteristics, laboratory findings, and radiologic and histopathological features. Logistic regression analyses were performed to explore factors related to the presence of fibrosis.Results: A total of 202 patients with HP were enrolled, including 87 (43.1%) NFHP patients and 115 (56.9%) FHP patients. Patients with FHP were older and more frequently presented with dyspnea, crackles, and digital clubbing than patients with NFHP. Serum levels of carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 153, gastrin-releasing peptide precursor, squamous cell carcinoma antigen, and antigen cytokeratin 21-1, and count of bronchoalveolar lavage (BAL) eosinophils were higher in the FHP group than in the NFHP group. BAL lymphocytosis was present in both groups, but less pronounced in the FHP group. Multivariable regression analyses revealed that older age, <20% of lymphocyte in BAL, and >= 1.75% of eosinophil in BAL were risk factors for the development of FHP. Twelve patients developed adverse outcomes, with a median survival time of 12.5 months, all of whom had FHP.Conclusions: Older age, <20% of lymphocyte in BAL, and >= 1.75% of eosinophil in BAL were risk factors associated with the development of FHP. Prognosis of patients with NFHP was better than that of patients with FHP. These results may provide insights into the mechanisms of fibrosis in HP.
引用
收藏
页码:2839 / 2846
页数:8
相关论文
共 50 条
  • [1] Clinical characteristics of hypersensitivity pneumonitis: non-fibrotic and fibrotic subtypes
    Chen Xueying
    Yang Xiaoyan
    Ren Yanhong
    Xie Bingbing
    Xie Sheng
    Zhao Ling
    Wang Shiyao
    Geng Jing
    Jiang Dingyuan
    Luo Sa
    He Jiarui
    Shu Shi
    Hu Yinan
    Zhu Lili
    Li Zhen
    Zhang Xinran
    Liu Min
    Dai Huaping
    中华医学杂志英文版, 2023, 136 (23)
  • [2] Distinct TNF-alpha and HLA polymorphisms associate with fibrotic and non-fibrotic subtypes of hypersensitivity pneumonitis
    Freitas, C.
    Lima, B.
    Melo, N.
    Mota, P.
    Novais-Bastos, H.
    Alves, H.
    Sokhatska, O.
    Delgado, L.
    Morais, A.
    PULMONOLOGY, 2023, 29 : S63 - S69
  • [3] GDF15 as a potential biomarker to distinguish fibrotic from non-fibrotic hypersensitivity pneumonitis
    A. Alarcon-Dionet
    A. Ruiz
    L. Chavez-Galan
    I. Buendia-Roldan
    M. Selman
    Scientific Reports, 14
  • [4] GDF15 as a potential biomarker to distinguish fibrotic from non-fibrotic hypersensitivity pneumonitis
    Alarcon-Dionet, A.
    Ruiz, A.
    Chavez-Galan, L.
    Buendia-Roldan, I.
    Selman, M.
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [5] A specific elastin fragment (ELP-3) as a potential serological biomarker to distinguish fibrotic from non-fibrotic hypersensitivity pneumonitis
    Simoes, Filipa B.
    Hoyer, Nils
    Draeby, Sandra
    Hansen, Annika H.
    Karsdal, Morten
    Leeming, Diana J.
    Sand, Jannie M. B.
    Shaker, Saher B.
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [6] Fibrotic hypersensitivity pneumonitis
    Fernandez Perez, Evans R.
    Brown, Kevin K.
    CURRENT PULMONOLOGY REPORTS, 2014, 3 (04) : 170 - 178
  • [7] Fibrotic hypersensitivity pneumonitis
    Evans R. Fernández Pérez
    Kevin K. Brown
    Current Respiratory Care Reports, 2014, 3 (4): : 170 - 178
  • [8] Decreased expression of transmembrane TNFR2 in lung leukocytes subpopulations of patients with non-fibrotic hypersensitivity pneumonitis compared with the fibrotic disease
    Chavez-Galan, Leslie
    Buendia-Roldan, Ivette
    Castillo-Castillo, Kelly
    Preciado-Garcia, Mario
    Ocana-Guzman, Ranferi
    Salgado, Alfonso
    Gaxiola, Miguel
    Selman, Moises
    CLINICAL IMMUNOLOGY, 2020, 215
  • [9] Vasoreactive pulmonary artery hypertension in non-fibrotic hypersensitive pneumonitis
    Gupta, Sushan
    Mohta, Avani
    Thameem, Danish
    BMJ CASE REPORTS, 2024, 17 (01)
  • [10] Management of fibrotic hypersensitivity pneumonitis
    Mullin, Monica L.
    Churg, Andrew
    Ryerson, Christopher J.
    CURRENT OPINION IN PULMONARY MEDICINE, 2022, 28 (05) : 421 - 431